2020 saw a special purpose acquisition company (SPAC) boom in the life sciences industry: 33 biopharma SPACs raised more than $6B globally. Now halfway into 2021, SPACs continue to show promise as a new way for emerging biopharmas to go public, but are they living up to the early hype?

In this virtual Forum, panelists will share their bullish or bearish thoughts on the recent surge in SPACs. Topics will include:

• The SPAC investment ecosystem
• Pros/cons about launching via a SPAC
• Navigating SPAC investing